🩸🧬 The use of ctDNA to monitor on-treatment response to anticancer agents is not there yet. Here, the RECIST group reviews the current evidence and outline the requirements for future studies towards plasma ctDNA standardization Clinical Cancer Research 👇🏼👇🏼👇🏼 aacrjournals.org/clincancerres/…

📣#LoMásLeído| 🥼​#BurnoutMédico| Casi el 6️⃣​0️⃣​% de los oncólogos europeos sufren burnout, afectando especialmente a los menores de 40 años con un 6️⃣​1️⃣​% ESMO - Eur. Oncology SEOM #ESMO24 César Serrano García #Oncología i.mtr.cool/eyuboqtvgp

🩸🧬 Willing to learn more about #ctDNA development in #GIST? Please come by to this #MeetTheExpert at #ESMO24 with me and Dr. Giovanni Grignani ✍️ 🗓 Today 15/09 🕒 4-5pm 🪧 Marbella Auditorium cc5

Looking forward to interesting #sarcoma session this afternoon at #ESMO2024 Definition and clinical implication of #response in localised sarcomas 🤔 sylvie bonvalot Kjetil Boye 📍4.30pm - Santander - Hall 5 🙌🏻 #sarcomapeeps Tom Wei-Wu Chen

✍️Results from the phase 3 maintenance trial of regorafenib vs placebo after doxorubicin in advanced #sarcoma 👍🏼Benefit in PFS (meets primary objective) 👎🏼No significance difference in mOS 💊Toxicity leading to dose reduction and interruptions #ESMO24 #ESMOAmbassadors

🧬MULTISARC trial studying NGS vs non-NGS driven treatment in #sarcoma #STS ✅ NGS + MTB is feasible 💊Therapeutic orientation in 54% ➡️ 20% pts could go to a clinical trial 🧐 What is the real objective benefit of NGS in pts with sarcoma #ESMO24 #ESMOAmbassadors

MULTISARC precision oncology trial across 17 🇫🇷 FSG sites ▪️Patients randomised to NGS v no NGS ✔️54% targettable alteration (n= 98/181 NGS arm) 👇Durva-olaparib sub study results #ESMO24

✍️Phase 3 MOTION trial in #TGCT: Vimseltinib vs placebo -RECIST 40% ORR -Tumor Volume Score 67% ORR -Clinically meaningful Improvement -Well tolerated and manageable adverse events ➡️ Vimseltinib is a well-deserved standard of care #ESMO24 #ESMOAmbassadors

📉LENVAGIST R-P2 trial in met #GIST presented by Jean-Yves Blay -Heavily pretreated population (>3 lines 50%) -mPFS 2.8mo vs 1 mo placebo -1 partial response (5%) ✍️MKIs with anti-KIT activity have (almost) always some degree of activity #ESMO24 #ESMOAmbassadors

Cancer in the young is on the rise worldwide, but the basis for this is not known. A new review covers it well, open-access cell.com/cell-reports-m… Alberto Bardelli Gianluca Mauri Cell Reports Medicine

Mañana #sarcoma #investigación 👇🏼👇🏼👇🏼

Clinical benefit and fragility evaluation of systemic therapy trials for advanced soft tissue #sarcoma acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

🎗20 de Septiembre, Día Nacional del #sarcoma ☺️ Hoy os quiero agradecer de corazón a tanta y tanta gente, que nos habéis ayudado y nos ayudáis en nuestra #investigación en sarcomas: Carlota, Amaia, Gloria, Patri, Cristina, María, Andrea y… Rozalén 🥰 Rozalén

Our cells detect foreign DNA to initiate immune responses to DNA viruses. These immune responses involve the production & secretion of type I interferons. Responses to DNA are now known to play central roles in many diseases, including autoimmune diseases & cancer. How DNA

Organoids from almost any type of carcinoma have been developed, but non-epithelial cancers lagged behind - until now! Here is our paper developing patient-derived sarcoma organoids from 110+ samples, 20+ types of sarcomas, rare bone and soft tissue tumors cell.com/cell-stem-cell…

Loss of SMARCB1 evokes targetable epigenetic vulnerabilities in Epithelioid Sarcoma biorxiv.org/cgi/content/sh… #biorxiv_cancer

#Salamanca #Vacaciones #FewDaysOff #Casa #Home #CiudadMásBonitaDelMundo

Quedan pocos días para la Sarcoma’s Week!: 📚 Curso anual Sarcomas (2-3 Oct) 💪 Workshop IMPERAS (2 Oct, 3ª Edición) 🔬1er Curso de Sarcomas de IMPERAS (3 Oct) ✍🏼Curso de Enfermería en Sarcomas (3 Oct) 🙌 Simposio de Pacientes (3 Oct) 🌍 GEIS International Symposium (4 Oct)

Recent research highlights extrachromosomal DNA role in cancer progression. By increasing oncogene copy numbers, enhancing transcription via 'ecDNA hubs,' & promoting genetic diversity, ecDNA drives rapid tumor evolution & treatment resistance. nature.com/articles/s4156…

New #JITC article: A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses bit.ly/4gE7Yup Nathan Seligson Sandra P D'Angelo, MD